Sophie Alexander 💙 presenting on ‘Prostate cancer ultra-hypofractionated RT: Does MRI-guided adaptation improve therapeutic ratio?’

Anuradha Krishnan presenting her work on hypofractionated curative chemoradiotherapy for bladder preservation in muscle invasive bladder cancer

Assessing a cord compression at T10
#radonc

Another great day at #ESTRO2024 rounded off with a fantastic talk by Sophie Alexander 💙 assessing the impact of ultra-hypofractionated MR-guided #adaptive radiotherapy for prostate cancer

My long time friend JamesBarberRT with a hugely thought-provoking talk around the move to hypofractionated RT and the impact this has on the patient experience in RT. Reduced visits are logistically great BUT our patients have less contact and perhaps less support #ESTRO24

10-yr Results of Moderately Hypofractionated Postoperative Radiotherapy in Ca Prostate

sciencedirect.com/science/articl…

#ESTRO24 Felipe Couñago PhD presenting HYPORT-ES results

hypofractionated postop RT adjuvant and salvage: 62.5 Gy / 25 fx

96% SRT, 54% received ADT, prophylactic nodal RT not allowed

✅Acute and late gr3+ GU/GI toxicity all <2% with median fu 23 mos
✅ 93% BFFS @ 36 mos

#radonc

Postoperative Hypofractionated Intensity-Modulated Radiotherapy With Concurrent Chemotherapy in Cervical Cancer The POHIM-CCRT Nonrandomized Controlled Trial.

jamanetwork.com/journals/jamao…

In Journal of the @NCCN - we analyzed #medicare data to estimate usage patterns for hypofractionated #radiotherapy for elderly pts with 🧠 tumors and found interesting differences in use by site of care. Great work with Kathryn Ries Tringale Memorial Sloan Kettering Radiation Oncology Memorial Sloan Kettering Cancer Center

doi.org/10.6004/jnccn.…

Physicists when the radonc comes by with a 'quick question'
#radonc

Felipe Couñago PhD presents additional data supporting hypofractionated prostate bed radiotherapy after biochemical relapse.

NCT04484038
407 pts phase II non randomized trial
62.5Gy in 25 fx
No pelvic RT
54% concurrent ADT

Excellent PSA control and very low toxicity

#ESTRO24

A recently published paper studied the feasibility of a re-irradiation treatment option for recurring glioblastoma, a type of cancer, whose data analysis was drafted by Venkat before starting at UNSW as a statistical consultant. [1/3]
doi.org/10.1007/s11060…

Interesting talk from Felipe Couñaho from GenesisCare España on Phase 2 trial of hypofractionated postoperative radiotherapy in prostate cancer #ESTRO24

Postoperative Hypofractionated IMRT With Concurrent Chemotherapy for Cervical Cancer | PracticeUpdate practiceupdate.com/content/postop…

🔝 #HighlyCitedPaper
Cost Minimization Analysis of Hypofractionated Radiotherapy
brnw.ch/21wJpXr
#breastcancer #costefficiency

Hypofractionated IMRT with concurrent chemotherapy appears to be well tolerated as post-operative treatment in patients with #cervicalcancer . Published in JAMA Oncology. brnw.ch/21wJnEj #gyncsm

• We are in #ESTRO24 !! This sunday, we will presented the results of the HYPORT-ES trial. This is a Spanish, Phase II trial of hypofractionated postoperative radiotherapy in prostate cancer .

• Happy to share table with big names of the Radiation Oncology prof. Barbara Jereczek-Fossa

GCR Resident Partner, Joaquín Carlos Ferrer Criado, Residente de Oncología Radioterápica, has shared more information about treating the first patient in Uruguay with the Fast Forward ultra-hypofractionated regime.

Check out our blogpost to learn more!👇
globalradiotherapy.org/post/gcr-resid…

Evaluating the Quality-of-Life Effect of Apical Spacing with Hyaluronic Acid Prior to Hypofractionated Prostate Radiation Therapy: A Secondary Analysis - Practical Radiation Oncology practicalradonc.org/article/S1879-…

IJROBP - The Red Journal mamayom really turning up the radonc publishing game